CMS Innovation Center Exploring ‘Array’ Of Cost-Lowering Medicare Payment Models
CMMI payment demonstrations are viewed as way of skirting statutory obstacles to experimenting with new approaches to reimbursement and could lead to significant drug pricing reforms if legislative efforts fail. However, HHS is not signaling an intent to pursue transformational new models at this point.
You may also be interested in...
Biopharma likely approves of the Administration’s concern that QALYs, a commonly used metric in cost effectiveness evaluations, may not be appropriate for drug pricing reform policies because it could disadvantage people with disabilities.
US Centers For Medicare and Medicaid Services doesn’t tip its hand on what, if anything, might replace the rule but says it is exploring ways to lower spending on Medicare Part B drugs.
After months of reticence about his Administration's plans for tackling drug pricing, Biden's executive order offers some clues about what might be in store and what kind of timeline they are working with.